Roles of Lipid Mediators in Kidney Injury

Seminars in Nephrology

Volumn 27, Issue 3, 2007, Pages 338-351

  Hao, Chuan Ming ^a   Breyer, Matthew D ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

Cyclooxygenase; diabetic nephropathy; lipoxygenase; nephritis; P450 monooxygenase; prostaglandin

Indexed keywords

12 HYDROXYICOSATETRAENOIC ACID; ANGIOTENSIN II; ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONIC ACID; CERAMIDE; CLOFIBRATE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN A; CYTOCHROME P450; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPOXYICOSATRIENOIC ACID; FENOFIBRATE; LEUKOTRIENE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROSTANOID RECEPTOR; TRANSFORMING GROWTH FACTOR BETA;

ALBUMINURIA; ARTICLE; CHRONIC KIDNEY DISEASE; COMBINATION CHEMOTHERAPY; DIABETIC NEPHROPATHY; DRUG MECHANISM; GLOMERULOSCLEROSIS; HEYMANN NEPHRITIS; HUMAN; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY ISCHEMIA; LUPUS ERYTHEMATOSUS NEPHRITIS; MONOTHERAPY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL;

ANIMALS; ARACHIDONIC ACIDS; CYCLOOXYGENASE INHIBITORS; CYTOCHROME P-450 ENZYME SYSTEM; DIABETIC NEPHROPATHIES; HUMANS; KIDNEY DISEASES; LEUKOTRIENES; LIPOXYGENASE; MODELS, BIOLOGICAL; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS;

EID: 34249110684     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2007.02.008     Document Type: Article

References (178)

1. Brash A.R. Arachidonic acid as a bioactive molecule. J Clin Invest 107 (2001) 1339-1345
2. Funk C.D. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294 (2001) 1871-1875
3. Fitzpatrick F.A., and Soberman R. Regulated formation of eicosanoids. J Clin Invest 107 (2001) 1347-1351
4. FitzGerald G.A., and Loll P. COX in a crystal ball: current status and future promise of prostaglandin research. J Clin Invest 107 (2001) 1335-1337
5. Capdevila J.H., Harris R.C., and Falck J.R. Microsomal cytochrome P450 and eicosanoid metabolism. Cell Mol Life Sci 59 (2002) 780-789
6. Smith W.L. Prostanoid biosynthesis and mechanisms of action. Am J Physiol 263 (1992) F181-F191
7. Hla T., Bishop-Bailey D., Liu C.H., et al. Cyclooxygenase-1 and -2 isoenzymes. Int J Biochem Cell Biol 31 (1999) 551-557
8. Bonventre J.V. The 85-kD cytosolic phospholipase A2 knockout mouse: a new tool for physiology and cell biology. J Am Soc Nephrol 10 (1999) 404-412
9. Kudo I., and Murakami M. Phospholipase A2 enzymes. Prostaglandins Other Lipid Mediat 68-69 (2002) 3-58
10. Shimizu T., Ohto T., and Kita Y. Cytosolic phospholipase A2: biochemical properties and physiological roles. IUBMB Life 58 (2006) 328-333
11. Clark J.D., Lin L.L., Kriz R.W., et al. A novel arachidonic acid-selective cytosolic PLA2 contains a Ca(2+)-dependent translocation domain with homology to PKC and GAP. Cell 65 (1991) 1043-1051
12. Clark J.D., Milona N., and Knopf J.L. Purification of a 110-kilodalton cytosolic phospholipase A2 from the human monocytic cell line U937. Proc Natl Acad Sci U S A 87 (1990) 7708-7712
13. Sharp J.D., White D.L., Chiou X.G., et al. Molecular cloning and expression of human Ca(2+)-sensitive cytosolic phospholipase A2. J Biol Chem 266 (1991) 14850-14853
14. Barnett R.L., Ruffini L., Hart D., et al. Mechanism of endothelin activation of phospholipase A2 in rat renal medullary interstitial cells. Am J Physiol 266 (1994) F46-F56
15. Resink T.J., Scott-Burden T., and Buhler F.R. Activation of phospholipase A2 by endothelin in cultured vascular smooth muscle cells. Biochem Biophys Res Commun 158 (1989) 279-286
16. Schramek H., Wang Y., Konieczkowski M., et al. Endothelin-1 stimulates cytosolic phospholipase A2 activity and gene expression in rat glomerular mesangial cells. Kidney Int 46 (1994) 1644-1652
17. Takakuwa T., Endo S., Nakae H., et al. Relationship between plasma levels of type II phospholipase A2, PAF acetylhydrolase, endothelin-1, and thrombomodulin in patients with infected burns. Res Commun Mol Pathol Pharmacol 86 (1994) 335-340
18. Dulin N.O., Alexander L.D., Harwalkar S., et al. Phospholipase A2-mediated activation of mitogen-activated protein kinase by angiotensin II. Proc Natl Acad Sci U S A 95 (1998) 8098-8102
19. Lehman J.J., Brown K.A., Ramanadham S., et al. Arachidonic acid release from aortic smooth muscle cells induced by [Arg8]vasopressin is largely mediated by calcium-independent phospholipase A2. J Biol Chem 268 (1993) 20713-20716
20. Liu Y., and Taylor C.W. Stimulation of arachidonic acid release by vasopressin in A7r5 vascular smooth muscle cells mediated by Ca2+-stimulated phospholipase A2. FEBS Lett 580 (2006) 4114-4120
21. Goto S., Nakamura H., Morooka H., et al. Role of reactive oxygen in phospholipase A2 activation by ischemia/reperfusion of the rat kidney. J Anesth 13 (1999) 90-93
22. Cybulsky A.V., Takano T., Papillon J., et al. The actin cytoskeleton facilitates complement-mediated activation of cytosolic phospholipase A2. Am J Physiol 286 (2004) F466-F476
23. Petry C., Huwiler A., Eberhardt W., et al. Hypoxia increases group IIA phospholipase A(2) expression under inflammatory conditions in rat renal mesangial cells. J Am Soc Nephrol 16 (2005) 2897-2905
24. Alexander L.D., Alagarsamy S., and Douglas J.G. Cyclic stretch-induced cPLA2 mediates ERK 1/2 signaling in rabbit proximal tubule cells. Kidney Int 65 (2004) 551-563
25. Sapirstein A., Spech R.A., Witzgall R., et al. Cytosolic phospholipase A2 (PLA2), but not secretory PLA2, potentiates hydrogen peroxide cytotoxicity in kidney epithelial cells. J Biol Chem 271 (1996) 21505-21513
26. Sheridan A.M., Force T., Yoon H.J., et al. PLIP, a novel splice variant of Tip60, interacts with group IV cytosolic phospholipase A(2), induces apoptosis, and potentiates prostaglandin production. Mol Cell Biol 21 (2001) 4470-4481
27. Boyanovsky B.B., van der Westhuyzen D.R., and Webb N.R. Group V secretory phospholipase A2-modified low density lipoprotein promotes foam cell formation by a SR-A- and CD36-independent process that involves cellular proteoglycans. J Biol Chem 280 (2005) 32746-32752
28. Fuentes L., Hernandez M., Fernandez-Aviles F.J., et al. Cooperation between secretory phospholipase A2 and TNF-receptor superfamily signaling: implications for the inflammatory response in atherogenesis. Circ Res 91 (2002) 681-688
29. Murakami M., and Kudo I. New phospholipase A(2) isozymes with a potential role in atherosclerosis. Curr Opin Lipidol 14 (2003) 431-436
30. Herschman H.R. Prostaglandin synthase 2. Biochim Biophys Acta 1299 (1996) 125-140
31. Breyer M.D., and Breyer R.M. Prostaglandin receptors: their role in regulating renal function. Curr Opin Nephrol Hypertens 9 (2000) 23-29
32. Narumiya S., and FitzGerald G.A. Genetic and pharmacological analysis of prostanoid receptor function. J Clin Invest 108 (2001) 25-30
33. Hao C.M., Redha R., Morrow J., et al. Peroxisome proliferator-activated receptor delta activation promotes cell survival following hypertonic stress. J Biol Chem 277 (2002) 21341-21345
34. Lim H., and Dey S.K. PPAR delta functions as a prostacyclin receptor in blastocyst implantation. Trends Endocrinol Metab 11 (2000) 137-142
35. Bernardo A., Levi G., and Minghetti L. Role of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) and its natural ligand 15-deoxy-Delta12, 14-prostaglandin J2 in the regulation of microglial functions. Eur J Neurosci 12 (2000) 2215-2223
36. Ward J.E., Gould H., Harris T., et al. PPAR gamma ligands, 15-deoxy-delta12,14-prostaglandin J2 and rosiglitazone regulate human cultured airway smooth muscle proliferation through different mechanisms. Br J Pharmacol 141 (2004) 517-525
37. Simmons D.L., Levy D.B., Yannoni Y., et al. Identification of a phorbol ester-repressible v-src-inducible gene. Proc Natl Acad Sci U S A 86 (1989) 1178-1182
38. Guan Y., Chang M., Cho W., et al. Cloning, expression, and regulation of rabbit cyclooxygenase-2 in renal medullary interstitial cells. Am J Physiol 273 (1997) F18-F26
39. Hla T., and Neilson K. Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci U S A 89 (1992) 7384-7388
40. Kujubu D.A., Fletcher B.S., Varnum B.C., et al. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 266 (1991) 12866-12872
41. Smith W.L., and Langenbach R. Why there are two cyclooxygenase isozymes. J Clin Invest 107 (2001) 1491-1495
42. Dinchuk J.E., Car B.D., Focht R.J., et al. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature 378 (1995) 406-409
43. Morham S.G., Langenbach R., Loftin C.D., et al. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 83 (1995) 473-482
44. Komhoff M., Wang J.L., Cheng H.F., et al. Cyclooxygenase-2-selective inhibitors impair glomerulogenesis and renal cortical development. Kidney Int 57 (2000) 414-422
45. Lim H., Paria B.C., Das S.K., et al. Multiple female reproductive failures in cyclooxygenase 2-deficient mice. Cell 91 (1997) 197-208
46. Bresalier R.S., Sandler R.S., Quan H., et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352 (2005) 1092-1102
47. Zewede T., and Mattson D.L. Inhibition of cyclooxygenase-2 in the rat renal medulla leads to sodium-sensitive hypertension. Hypertension 44 (2004) 4248
48. Zhang J., Ding E.L., and Song Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. JAMA 296 (2006) 1619-1632
49. Harris R.C., McKanna J.A., Akai Y., et al. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 94 (1994) 2504-2510
50. Yang T., Singh I., Pham H., et al. Regulation of cyclooxygenase expression in the kidney by dietary salt intake. Am J Physiol 274 (1998) F481-F489
51. Castrop H., Schweda F., Schumacher K., et al. Role of renocortical cyclooxygenase-2 for renal vascular resistance and macula densa control of renin secretion. J Am Soc Nephrol 12 (2001) 867-874
52. Hao C.M., Komhoff M., Guan Y., et al. Selective targeting of cyclooxygenase-2 reveals its role in renal medullary interstitial cell survival. Am J Physiol 277 (1999) F352-F359
53. FitzGerald G.A. COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov 2 (2003) 879-890
54. Jakobsson P.J., Thoren S., Morgenstern R., et al. Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc Natl Acad Sci U S A 96 (1999) 7220-7225
55. Tanioka T., Nakatani Y., Semmyo N., et al. Molecular identification of cytosolic prostaglandin E2 synthase that is functionally coupled with cyclooxygenase-1 in immediate prostaglandin E2 biosynthesis. J Biol Chem 275 (2000) 32775-32782
56. Tanikawa N., Ohmiya Y., Ohkubo H., et al. Identification and characterization of a novel type of membrane-associated prostaglandin E synthase. Biochem Biophys Res Commun 291 (2002) 884-889
57. Lazarus M., Kubata B.K., Eguchi N., et al. Biochemical characterization of mouse microsomal prostaglandin E synthase-1 and its colocalization with cyclooxygenase-2 in peritoneal macrophages. Arch Biochem Biophys 397 (2002) 336-341
58. Murakami M., Nakatani Y., Tanioka T., et al. Prostaglandin E synthase. Prostaglandins Other Lipid Mediat 68-69 (2002) 383-399
59. Urade Y., and Eguchi N. Lipocalin-type and hematopoietic prostaglandin D synthases as a novel example of functional convergence. Prostaglandins Other Lipid Mediat 68-69 (2002) 375-382
60. Urade Y., and Hayaishi O. Biochemical, structural, genetic, physiological, and pathophysiological features of lipocalin-type prostaglandin D synthase. Biochim Biophys Acta 1482 (2000) 259-271
61. Watanabe K. Prostaglandin F synthase. Prostaglandins Other Lipid Mediat 68-69 (2002) 401-407
62. Lee S.C., and Levine L. Purification and regulatory properties of chicken heart prostaglandin E 9-ketoreductase. J Biol Chem 250 (1975) 4549-4555
63. Westbrook C., and Jarabak J. Purification and partial characterization of an NADH-linked delta13-15-ketoprostaglandin reductase from human placenta. Biochem Biophys Res Commun 66 (1975) 541-546
64. Tilley S.L., Coffman T.M., and Koller B.H. Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. J Clin Invest 108 (2001) 15-23
65. Schneider A., Zhang Y., Zhang M., et al. Membrane-associated PGE synthase-1 (mPGES-1) is coexpressed with both COX-1 and COX-2 in the kidney. Kidney Int 65 (2004) 1205-1213
66. Vitzthum H., Abt I., Einhellig S., et al. Gene expression of prostanoid forming enzymes along the rat nephron. Kidney Int 62 (2002) 1570-1581
67. Yang G., Chen L., Zhang Y., et al. Expression of mouse membrane-associated prostaglandin E(2) synthase-2 (mPGES-2) along the urogenital tract. Biochim Biophys Acta 1761 (2006) 1459-1468
68. Zhang Y., Schneider A., Rao R., et al. Genomic structure and genitourinary expression of mouse cytosolic prostaglandin E(2) synthase gene. Biochim Biophys Acta 1634 (2003) 15-23
69. Qi Z., Cai H., Morrow J.D., et al. Differentiation of cyclooxygenase 1- and 2-derived prostanoids in mouse kidney and aorta. Hypertension 48 (2006) 323-328
70. Cronstein B.N., and Weissmann G. Targets for antiinflammatory drugs. Annu Rev Pharmacol Toxicol 35 (1995) 449-462
71. Breyer M.D., and Breyer R.M. G protein-coupled prostanoid receptors and the kidney. Annu Rev Physiol 63 (2001) 579-605
72. Saito O., Guan Y., Qi Z., et al. Expression of the prostaglandin F receptor (FP) gene along the mouse genitourinary tract. Am J Physiol 284 (2003) F1164-F1170
73. Kennedy C.R., Zhang Y., Brandon S., et al. Salt-sensitive hypertension and reduced fertility in mice lacking the prostaglandin EP2 receptor. Nat Med 5 (1999) 217-220
74. Tilley S.L., Audoly L.P., Hicks E.H., et al. Reproductive failure and reduced blood pressure in mice lacking the EP2 prostaglandin E2 receptor. J Clin Invest 103 (1999) 1539-1545
75. Breyer R.M., Davis L.S., Nian C., et al. Cloning and expression of the rabbit prostaglandin EP4 receptor. Am J Physiol 270 (1996) F485-F493
76. Hempel S.L., Monick M.M., and Hunninghake G.W. Lipopolysaccharide induces prostaglandin H synthase-2 protein and mRNA in human alveolar macrophages and blood monocytes. J Clin Invest 93 (1994) 391-396
77. Rajakariar R., Yaqoob M.M., and Gilroy D.W. COX-2 in inflammation and resolution. Mol Interv 6 (2006) 199-207
78. Tomasoni S., Noris M., Zappella S., et al. Upregulation of renal and systemic cyclooxygenase-2 in patients with active lupus nephritis. J Am Soc Nephrol 9 (1998) 1202-1212
79. Hartner A., Pahl A., Brune K., et al. Upregulation of cyclooxygenase-1 and the PGE2 receptor EP2 in rat and human mesangioproliferative glomerulonephritis. Inflamm Res 49 (2000) 345-354
80. Waldner C., Heise G., Schror K., et al. COX-2 inhibition and prostaglandin receptors in experimental nephritis. Eur J Clin Invest 33 (2003) 969-975
81. Schneider A., Harendza S., Zahner G., et al. Cyclooxygenase metabolites mediate glomerular monocyte chemoattractant protein-1 formation and monocyte recruitment in experimental glomerulonephritis. Kidney Int 55 (1999) 430-441
82. Zoja C., Benigni A., Noris M., et al. Mycophenolate mofetil combined with a cyclooxygenase-2 inhibitor ameliorates murine lupus nephritis. Kidney Int 60 (2001) 653-663
83. Takano T., Cybulsky A.V., Cupples W.A., et al. Inhibition of cyclooxygenases reduces complement-induced glomerular epithelial cell injury and proteinuria in passive Heymann nephritis. J Pharmacol Exp Ther 305 (2003) 240-249
84. Heise G., Grabensee B., Schror K., et al. Different actions of the cyclooxygenase 2 selective inhibitor flosulide in rats with passive Heymann nephritis. Nephron 80 (1998) 220-226
85. Kitahara M., Eitner F., Ostendorf T., et al. Selective cyclooxygenase-2 inhibition impairs glomerular capillary healing in experimental glomerulonephritis. J Am Soc Nephrol 13 (2002) 1261-1270
86. Breyer M.D., Bottinger E., Brosius F.C., et al. Diabetic nephropathy: of mice and men. Adv Chronic Kidney Dis 12 (2005) 128-145
87. McGowan T., McCue P., and Sharma K. Diabetic nephropathy. Clin Lab Med 21 (2001) 111-146
88. Craven P.A., Caines M.A., and DeRubertis F.R. Sequential alterations in glomerular prostaglandin and thromboxane synthesis in diabetic rats: relationship to the hyperfiltration of early diabetes. Metabolism 36 (1987) 95-103
89. Moel D.I., Safirstein R.L., McEvoy R.C., et al. Effect of aspirin on experimental diabetic nephropathy. J Lab Clin Med 110 (1987) 300-307
90. Komers R., Lindsley J.N., Oyama T.T., et al. Immunohistochemical and functional correlations of renal cyclooxygenase-2 in experimental diabetes. J Clin Invest 107 (2001) 889-898
91. Cheng H.F., Wang C.J., Moeckel G.W., et al. Cyclooxygenase-2 inhibitor blocks expression of mediators of renal injury in a model of diabetes and hypertension. Kidney Int 62 (2002) 929-939
92. Dey A., Williams R.S., Pollock D.M., et al. Altered kidney CYP2C and cyclooxygenase-2 levels are associated with obesity-related albuminuria. Obes Res 12 (2004) 1278-1289
93. Komers R., Zdychova J., Cahova M., et al. Renal cyclooxygenase-2 in obese Zucker (fatty) rats. Kidney Int 67 (2005) 2151-2158
94. Khan K.N., Stanfield K.M., Harris R.K., et al. Expression of cyclooxygenase-2 in the macula densa of human kidney in hypertension, congestive heart failure, and diabetic nephropathy. Ren Fail 23 (2001) 321-330
95. Nasrallah R., Xiong H., and Hebert R.L. Renal prostaglandin E2 receptor (EP) expression profile is altered in streptozotocin and B6-Ins2Akita type I-diabetic mice. Am J Physiol 292 (2007) F278-F284
96. Makino H., Tanaka I., Mukoyama M., et al. Prevention of diabetic nephropathy in rats by prostaglandin E receptor EP1-selective antagonist. J Am Soc Nephrol 13 (2002) 1757-1765
97. Xu S., Jiang B., Maitland K.A., et al. The thromboxane receptor antagonist S18886 attenuates renal oxidant stress and proteinuria in diabetic apolipoprotein E-deficient mice. Diabetes 55 (2006) 110-119
98. Pelayo J.C., and Shanley P.F. Glomerular and tubular adaptive responses to acute nephron loss in the rat. Effect of prostaglandin synthesis inhibition. J Clin Invest 85 (1990) 1761-1769
99. Nath K.A., Chmielewski D.H., and Hostetter T.H. Regulatory role of prostanoids in glomerular microcirculation of remnant nephrons. Am J Physiol 252 (1987) F829-F837
100. Cheng H., Zhang M., Moeckel G.W., et al. Expression of mediators of renal injury in the remnant kidney of ROP mice is attenuated by cyclooxygenase-2 inhibition. Nephron Exp Nephrol 101 (2005) e75-e85
101. Wang J.L., Cheng H.F., Shappell S., et al. A selective cyclooxygenase-2 inhibitor decreases proteinuria and retards progressive renal injury in rats. Kidney Int 57 (2000) 2334-2342
102. Brash A.R. Lipoxygenases: occurrence, functions, catalysis, and acquisition of substrate. J Biol Chem 274 (1999) 23679-23682
103. Funk C.D., Chen X.S., Johnson E.N., et al. Lipoxygenase genes and their targeted disruption. Prostaglandins Other Lipid Mediat 68-69 (2002) 303-312
104. Lewis R.A., and Austen K.F. Molecular determinants for functional responses to the sulfidopeptide leukotrienes: metabolism and receptor subclasses. J Allergy Clin Immunol 74 (1984) 369-372
105. Lewis R.A., Austen K.F., and Soberman R.J. Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N Engl J Med 323 (1990) 645-655
106. Samuelsson B., Dahlen S.E., Lindgren J.A., et al. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 237 (1987) 1171-1176
107. Steinhilber D. 5-Lipoxygenase: a target for antiinflammatory drugs revisited. Curr Med Chem 6 (1999) 71-85
108. Funk C.D., and Chen X.S. 5-Lipoxygenase and leukotrienes. Transgenic mouse and nuclear targeting studies. Am J Respir Crit Care Med 161 (2000) S120-S124
109. Mehrabian M., and Allayee H. 5-lipoxygenase and atherosclerosis. Curr Opin Lipidol 14 (2003) 447-457
110. Werz O. 5-lipoxygenase: cellular biology and molecular pharmacology. Curr Drug Targets Inflamm Allergy 1 (2002) 23-44
111. Chen X.S., Sheller J.R., Johnson E.N., et al. Role of leukotrienes revealed by targeted disruption of the 5-lipoxygenase gene. Nature 372 (1994) 179-182
112. Natarajan R., and Nadler J.L. Lipid inflammatory mediators in diabetic vascular disease. Arterioscler Thromb Vasc Biol 24 (2004) 1542-1548
113. Dailey L.A., and Imming P. 12-Lipoxygenase: classification, possible therapeutic benefits from inhibition, and inhibitors. Curr Med Chem 6 (1999) 389-398
114. Spokas E.G., Rokach J., and Wong P.Y. Leukotrienes, lipoxins, and hydroxyeicosatetraenoic acids. Methods Mol Biol 120 (1999) 213-247
115. Tang K., and Honn K.V. Lipoxygenase metabolites and cancer metastasis. Adv Exp Med Biol 422 (1997) 71-84
116. Zhao L., and Funk C.D. Lipoxygenase pathways in atherogenesis. Trends Cardiovasc Med 14 (2004) 191-195
117. Cyrus T., Pratico D., Zhao L., et al. Absence of 12/15-lipoxygenase expression decreases lipid peroxidation and atherogenesis in apolipoprotein e-deficient mice. Circulation 103 (2001) 2277-2282
118. Cyrus T., Witztum J.L., Rader D.J., et al. Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice. J Clin Invest 103 (1999) 1597-1604
119. Reddy M.A., Kim Y.S., Lanting L., et al. Reduced growth factor responses in vascular smooth muscle cells derived from 12/15-lipoxygenase-deficient mice. Hypertension 41 (2003) 1294-1300
120. Zhao L., Cuff C.A., Moss E., et al. Selective interleukin-12 synthesis defect in 12/15-lipoxygenase-deficient macrophages associated with reduced atherosclerosis in a mouse model of familial hypercholesterolemia. J Biol Chem 277 (2002) 35350-35356
121. Badr K.F. Lipoxygenases as therapeutic targets in the acute and subacute phases of glomerular immune injury. Contrib Nephrol 118 (1996) 113-125
122. Imig J.D. Eicosanoids and renal vascular function in diseases. Clin Sci (Lond) 111 (2006) 21-34
123. Reinhold S.W., Vitzthum H., Filbeck T., et al. Gene expression of 5-, 12-, and 15-lipoxygenases and leukotriene receptors along the rat nephron. Am J Physiol 290 (2006) F864-F872
124. Badr K.F. Five-lipoxygenase products in glomerular immune injury. J Am Soc Nephrol 3 (1992) 907-915
125. Katoh T., Lianos E.A., Fukunaga M., et al. Leukotriene D4 is a mediator of proteinuria and glomerular hemodynamic abnormalities in passive Heymann nephritis. J Clin Invest 91 (1993) 1507-1515
126. Yiu S.S., Zhao X., Inscho E.W., et al. 12-Hydroxyeicosatetraenoic acid participates in angiotensin II afferent arteriolar vasoconstriction by activating L-type calcium channels. J Lipid Res 44 (2003) 2391-2399
127. Gonzalez-Nunez D., Sole M., Natarajan R., et al. 12-Lipoxygenase metabolism in mouse distal convoluted tubule cells. Kidney Int 67 (2005) 178-186
128. Xu Z.G., Li S.L., Lanting L., et al. Relationship between 12/15-lipoxygenase and COX-2 in mesangial cells: potential role in diabetic nephropathy. Kidney Int 69 (2006) 512-519
129. Kang S.W., Adler S.G., Nast C.C., et al. 12-lipoxygenase is increased in glucose-stimulated mesangial cells and in experimental diabetic nephropathy. Kidney Int 59 (2001) 1354-1362
130. Antonipillai I., Nadler J., Vu E.J., et al. A 12-lipoxygenase product, 12-hydroxyeicosatetraenoic acid, is increased in diabetics with incipient and early renal disease. J Clin Endocrinol Metab 81 (1996) 1940-1945
131. Kim Y.S., Xu Z.G., Reddy M.A., et al. Novel interactions between TGF-{beta}1 actions and the 12/15-lipoxygenase pathway in mesangial cells. J Am Soc Nephrol 16 (2005) 352-362
132. Anning P.B., Coles B., Bermudez-Fajardo A., et al. Elevated endothelial nitric oxide bioactivity and resistance to angiotensin-dependent hypertension in 12/15-lipoxygenase knockout mice. Am J Pathol 166 (2005) 653-662
133. Kim Y.S., Reddy M.A., Lanting L., et al. Differential behavior of mesangial cells derived from 12/15-lipoxygenase knockout mice relative to control mice. Kidney Int 64 (2003) 1702-1714
134. McGiff J.C., and Quilley J. 20-hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids and blood pressure. Curr Opin Nephrol Hypertens 10 (2001) 231-237
135. Roman R.J. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 82 (2002) 131-185
136. Capdevila J.H., and Falck J.R. Biochemical and molecular properties of the cytochrome P450 arachidonic acid monooxygenases. Prostaglandins Other Lipid Mediat 68-69 (2002) 325-344
137. Zhao X., and Imig J.D. Kidney CYP450 enzymes: biological actions beyond drug metabolism. Curr Drug Metab 4 (2003) 73-84
138. Harder D.R., Gebremedhin D., Narayanan J., et al. Formation and action of a P-450 4A metabolite of arachidonic acid in cat cerebral microvessels. Am J Physiol 266 (1994) H2098-H2107
139. Imig J.D., Zou A.P., Stec D.E., et al. Formation and actions of 20-hydroxyeicosatetraenoic acid in rat renal arterioles. Am J Physiol 270 (1996) R217-R227
140. Oyekan A.O., McAward K., Conetta J., et al. Endothelin-1 and CYP450 arachidonate metabolites interact to promote tissue injury in DOCA-salt hypertension. Am J Physiol 276 (1999) R766-R775
141. Oyekan A.O., Youseff T., Fulton D., et al. Renal cytochrome P450 omega-hydroxylase and epoxygenase activity are differentially modified by nitric oxide and sodium chloride. J Clin Invest 104 (1999) 1131-1137
142. Imig J.D., and Deichmann P.C. Afferent arteriolar responses to ANG II involve activation of PLA2 and modulation by lipoxygenase and P-450 pathways. Am J Physiol 273 (1997) F274-F282
143. Zou A.P., Fleming J.T., Falck J.R., et al. 20-HETE is an endogenous inhibitor of the large-conductance Ca(2+)-activated K+ channel in renal arterioles. Am J Physiol 270 (1996) R228-R237
144. Roman R.J., Maier K.G., Sun C.W., et al. Renal and cardiovascular actions of 20-hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids. Clin Exp Pharmacol Physiol 27 (2000) 855-865
145. Wei Y., Lin D.H., Kemp R., et al. Arachidonic acid inhibits epithelial Na channel via cytochrome P450 (CYP) epoxygenase-dependent metabolic pathways. J Gen Physiol 124 (2004) 719-727
146. Nakagawa K., Holla V.R., Wei Y., et al. Salt-sensitive hypertension is associated with dysfunctional Cyp4a10 gene and kidney epithelial sodium channel. J Clin Invest 116 (2006) 1696-1702
147. Capdevila J.H., and Falck J.R. The CYP P450 arachidonic acid monooxygenases: from cell signaling to blood pressure regulation. Biochem Biophys Res Commun 285 (2001) 571-576
148. Grundy S.M., Brewer Jr. H.B., Cleeman J.I., et al. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109 (2004) 433-438
149. Kurella M., Lo J.C., and Chertow G.M. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol 16 (2005) 2134-2140
150. Chen J., Muntner P., Hamm L.L., et al. Insulin resistance and risk of chronic kidney disease in nondiabetic US adults. J Am Soc Nephrol 14 (2003) 469-477
151. Chen J., Wildman R.P., Hamm L.L., et al. Association between inflammation and insulin resistance in U.S. nondiabetic adults: results from the Third National Health and Nutrition Examination Survey. Diabetes Care 27 (2004) 2960-2965
152. Peralta C.A., Kurella M., Lo J.C., et al. The metabolic syndrome and chronic kidney disease. Curr Opin Nephrol Hypertens 15 (2006) 361-365
153. Wang M.H., Stec D.E., Balazy M., et al. Cloning, sequencing, and cDNA-directed expression of the rat renal CYP4A2: arachidonic acid omega-hydroxylation and 11,12-epoxidation by CYP4A2 protein. Arch Biochem Biophys 336 (1996) 240-250
154. Zhao X., Quigley J.E., Yuan J., et al. PPAR-alpha activator fenofibrate increases renal CYP-derived eicosanoid synthesis and improves endothelial dilator function in obese Zucker rats. Am J Physiol 290 (2006) H2187-H2195
155. Zhou Y., Lin S., Chang H.H., et al. Gender differences of renal CYP-derived eicosanoid synthesis in rats fed a high-fat diet. Am J Hypertens 18 (2005) 530-537
156. Luft F.C., Mervaala E., Muller D.N., et al. Hypertension-induced end-organ damage: a new transgenic approach to an old problem. Hypertension 33 (1999) 212-218
157. Theuer J., Dechend R., Muller D.N., et al. Angiotensin II induced inflammation in the kidney and in the heart of double transgenic rats. BMC Cardiovasc Disord 2 (2002) 3
158. Muller D.N., Theuer J., Shagdarsuren E., et al. A peroxisome proliferator-activated receptor-alpha activator induces renal CYP2C23 activity and protects from angiotensin II-induced renal injury. Am J Pathol 164 (2004) 521-532
159. Kaergel E., Muller D.N., Honeck H., et al. P450-dependent arachidonic acid metabolism and angiotensin II-induced renal damage. Hypertension 40 (2002) 273-279
160. Theuer J., Shagdarsuren E., Muller D.N., et al. Inducible NOS inhibition, eicosapentaenoic acid supplementation, and angiotensin II-induced renal damage. Kidney Int 67 (2005) 248-258
161. Miyazono M., Zhu D., Nemenoff R., et al. Increased epoxyeicosatrienoic acid formation in the rat kidney during liver cirrhosis. J Am Soc Nephrol 14 (2003) 1766-1775
162. Hercule H., and Oyekan A. Renal cytochrome p450 oxygenases and preglomerular vascular response to arachidonic acid and endothelin-1 following ischemia/reperfusion. J Pharmacol Exp Ther 302 (2002) 717-724
163. McCarthy E.T., Sharma R., and Sharma M. Protective effect of 20-hydroxyeicosatetraenoic acid (20-HETE) on glomerular protein permeability barrier. Kidney Int 67 (2005) 152-156
164. Ito O., Omata K., Ito S., et al. Effects of converting enzyme inhibitors on renal P-450 metabolism of arachidonic acid. Am J Physiol 280 (2001) R822-R830
165. Nakamura M., Imaoka S., Miura K., et al. Induction of cytochrome P450 isozymes in rat renal microsomes by cyclosporin A. Biochem Pharmacol 48 (1994) 1743-1746
166. Yoshimura R., Yoshimura N., Ohmachi T., et al. Effect of immunosuppressive drugs (CsA, FK 506, rapamycin) on the kidney microsomal cytochrome P-450 system in the rat. Transplant Proc 26 (1994) 2890
167. Hannun Y.A. Functions of ceramide in coordinating cellular responses to stress. Science 274 (1996) 1855-1859
168. Zhang Y., and Kolesnick R. Signaling through the sphingomyelin pathway. Endocrinology 136 (1995) 4157-4160
169. Pena L.A., Fuks Z., and Kolesnick R. Stress-induced apoptosis and the sphingomyelin pathway. Biochem Pharmacol 53 (1997) 615-621
170. Ueda N., Camargo S.M., Hong X., et al. Role of ceramide synthase in oxidant injury to renal tubular epithelial cells. J Am Soc Nephrol 12 (2001) 2384-2391
171. Ueda N., Kaushal G.P., Hong X., et al. Role of enhanced ceramide generation in DNA damage and cell death in chemical hypoxic injury to LLC-PK1 cells. Kidney Int 54 (1998) 399-406
172. Zager R.A., Conrad S., Lochhead K., et al. Altered sphingomyelinase and ceramide expression in the setting of ischemic and nephrotoxic acute renal failure. Kidney Int 53 (1998) 573-582
173. Zager R.A., Iwata M., Conrad D.S., et al. Altered ceramide and sphingosine expression during the induction phase of ischemic acute renal failure. Kidney Int 52 (1997) 60-70
174. Kalhorn T., and Zager R.A. Renal cortical ceramide patterns during ischemic and toxic injury: assessments by HPLC-mass spectrometry. Am J Physiol 277 (1999) F723-F733
175. Zager R.A., Conrad D.S., and Burkhart K. Ceramide accumulation during oxidant renal tubular injury: mechanisms and potential consequences. J Am Soc Nephrol 9 (1998) 1670-1680
176. Itoh Y., Yano T., Sendo T., et al. Involvement of de novo ceramide synthesis in radiocontrast-induced renal tubular cell injury. Kidney Int 69 (2006) 288-297
177. Basnakian A.G., Ueda N., Hong X., et al. Ceramide synthase is essential for endonuclease-mediated death of renal tubular epithelial cells induced by hypoxia-reoxygenation. Am J Physiol 288 (2005) F308-F314
178. Yi F., Zhang A.Y., Janscha J.L., et al. Homocysteine activates NADH/NADPH oxidase through ceramide-stimulated Rac GTPase activity in rat mesangial cells. Kidney Int 66 (2004) 1977-1987